Skip to content
Screener

Evolus EOLS Shares (Diluted)

Shares (Diluted) at other companies

AbbVie logo
AbbVieABBV
1.8B0.0%

Other financials

Income statement

See full
Revenue$84.1M+21.2%
Gross profit$57.2M+26.2%
Operating income-$4.5M+55.5%
Net income-$8.1M+53.0%
EPS (diluted)-$0.12+55.6%

Balance sheet

See full
Cash & equivalents$45.2M-26.8%
Total debt$164.8M+12.3%
Total equity-$30.9M-65.7%
Total assets$248.0M+8.4%

Cash flow

See full
Operating cash flow-$3.6M+85.5%
CapEx$50.0K-92.7%
Free cash flow-$3.6M+85.7%

Valuation

See full
Market cap$501.32M+31.0%
Enterprise value$620.96M+32.8%
P/S1.6×+0.2×

Profitability

See full
Gross margin66.7%-0.4pp
Operating margin-13.7%-1.9pp
Net margin-10.9%-3.7pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio1.7×-0.6×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Evolus’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:56 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053468

FAQ

What is Evolus's shares (diluted)?
Evolus (EOLS) reported shares (diluted) of 65.9M in Q2 2026.
How has Evolus's shares (diluted) changed year-over-year?
Evolus's shares (diluted) increased by 2.2% year-over-year, from 64.5M to 65.9M.
What is the long-term trend for Evolus's shares (diluted)?
Over 4 years (2021 to 2025), Evolus's shares (diluted) has grown at a 6.9% compound annual growth rate (CAGR), from 197M to 257.4M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Evolus's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude